Bayer: Pipeline, Products, Performance, Potential

Date: November 22, 2010
Pages: 136
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B19830E7A8CEN
Leaflet:

Download PDF Leaflet

Bayer: Pipeline, Products, Performance, Potential
Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials, and organised into three subgroups, namely HealthCare, CropScience and MaterialScience. Following Bayer's acquisition of Schering AG on 23rd June 2006, Schering was renamed Bayer Schering Pharma and its integration into the Pharmaceuticals division of Bayer HealthCare is now under way. Bayer Schering Pharma is expected to contribute to over half the revenues of Bayer HealthCare.

Bayer HealthCare's combined pharmaceuticals business is characterised by a well-balanced portfolio comprised of business units such as oncology, cardiology/haematology and gynaecology. In addition, the combined biotech platform provides a sound basis for further growth, including such products as Schering's Betaseron (interferon beta-1b) and Leukine (sargramostim), together with Bayer’s genetically-engineered Factor VIII Kogenate. Current growth drivers include: Avalox/Avelox (moxifloxacin), Betaferon/Betaseron (interferon beta-1b), Kogenate (Factor VIII), Levitra (vardenafil), Mirena (levonorgestrel), Yasmin (ethinyloestradiol+drospirenone) and Aspirin Cardio. By combining and consolidating the research and development activities of the two companies Bayer has achieved a more focused and balanced pipeline.

The acquisition of Schering AG, the largest corporate transaction in Bayer's history, enhanced the product portfolio and research and development pipeline providing a strong basis on which to build future success for Bayer HealthCare and thus the Bayer Group. Bayer is expecting HealthCare to account for nearly 50 per cent of Group sales in the future.

The integration of Schering is proceeding faster than expected and the acquisition has strengthened the Bayer Group's global market position in the pharmaceutical business as it copes with declining sales for many of its previously top-selling products, specifically Cipro.

Bayer's overall strategy of focusing its portfolio has continued with the divestment of the diagnostics business to Siemens Medical Solutions, followed by the subsidiaries of HC Starck and Wolff Walsrode. Since Bayer has acquired a diagnostics imaging business with the acquisition of Schering, this would seem to be a possible candidate for divestiture in the future.

The withdrawal of Trasylol is a notable setback for the company, especially following the withdrawal of Baycol/Lipobay around six years earlier. Both products managed to reach the market despite safety issues that subsequently led to withdrawal. This has led to company-wide review of Bayer Schering’s development and review processes. These two incidents occurring in such a short space of time could have some impact on Bayer’s profile in the pharmaceutical market.

This new strategic analysis report Bayer: Pipeline • Products • Performance • Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

More Information...

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting
Primary Care
  Adalat (nifedipine)
  Avelox/Avalox (moxifloxacin)
  Cipro/Ciprobay (ciprofloxacin)
  Glucobay (acarbose)
  Kinzalmono (telmisartan)
  Levitra/Vivanza (vardenafil)
Women's Healthcare
  Angeliq (drospirenone+oestradiol)
  Mirena (levonorgestrel)
  Yasmin (drospirenone+ ethinyloestradiol)
Diagnostic Imaging
  Magnevist (gadopentetate meglumine)
  Vasovist (gadolinium-chelate)
Specialized Therapeutics
  Betaferon/Betaseron (interferon beta-1b)
  Sativex (delta-9-tetrahydrocannabinol+ cannabidiol)
Hematology/Cardiology
  Kogenate/Kogenate FS (Factor VIII)
  Recothrom (recombinant human thrombin [rThrombin])
  Trasylol (aprotinin)
  Xarelto (rivaroxaban)
Oncology
  Nexavar (sorafenib)
  Zevalin (ibritumomab tiuxetan)

OPERATIONAL DATA

A wealth of background and detail
  A full 5-year financial performance assessment
  Key agreements
  Infrastructure
  Subsidiaries and joint ventures
Latest Results

EXECUTIVE SUMMARY

Introduction
Financial Performance 2009
  Business Segment Performance
Company Strategy
  Research and Development Strategy
  Key Agreements
  Mergers, Acquisitions and Divestitures
  Manufacturing
  Employees
Product Performance Forecasts
Pipeline Analysis
  Discontinued Projects
Other Factors Affecting The Bottom Line
Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

PRIMARY CARE

Marketed Products
  Avelox
  Azlin
  Baypen
  Biltricide
  Canesten
  Cipro
  Diastabol
  Fosrenol
  Glucobay
  Levitra
  Mycospor
  Nimotop
  Pro-viron
R&D Projects
NKTR-061

WOMEN'S HEALTHCARE

Marketed Products
  Angeliq
  Fidencia
  Cliane
  Climara
  Climodien 2/2 / Climodien 1/2
  Diane
  Menostar
  Microgynon
  Natazia
  Nuvelle TS
  Primolut
  Qlaira
  Tetragynon
  Valette
R&D Projects

SPECIALIZED THERAPEUTICS

Marketed Products
  Betaseron
  Cipramil
  Dopergin
  Noctamid
  Sativex
R&D Projects
  VEGF Trap-Eye

HAEMATOLOGY / CARDIOLOGY

Marketed Products
  Adalat
  Baypress
  Betapace
  Kogenate
  Quinaglute
  Recothrom
  Refludan
  Syscor
  Ventavis
  Xarelto
R&D Projects
  Riociguat

ONCOLOGY

Marketed Products
  Bonefos
  Depostat
  Nexavar
  Primoteston Depot
  Zevalin
R&D Projects
  Alpharadin
  Antiprogestin
  L19
  Regorafenib
  Sagopilone

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2009

APPENDIX 2 - KEY AGREEMENTS

Abbott
Actimis Pharmaceuticals
Activaero Technologies GmBH
Algeta ASA
Amerinet Inc
Ardea Biosciences Inc
Asklepios Biopharmaceutical Inc
Astex Technology
AstraZeneca
Avid Radiopharmaceuticals Inc
Barr Laboratories Inc
Biogen Idec/Cell Therapeutics Inc
Bioton SA
Boehringer Ingelheim
Celera Genomics
Cell Therapeutics Inc
ChemDiv Inc
CoTherix Inc
CSL Behring
CuraGen Corporation
Cytogen Corporation
Daiichi Sankyo
DARA Biosciences Inc
deCODE genetics
Dyax Corporation
E-Z-EM Inc
EPIX Pharmaceuticals
First Horizon Pharmaceutical Corporation
Favrille Inc
Fresenius Kabi AG
Genstruct Inc
Genzyme Corporation
GlaxoSmithKline
GW Pharmaceuticals plc
Indevus Pharmaceuticals Inc
ImmunoGen Inc
Johnson & Johnson
Mallinckrodt Inc
Memory Pharmaceuticals Inc
Micromet Inc
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma
Monash University
Morphosys AG
Nektar Therapeutics Corporation
Novartis
OncoGeneX Pharmaceuticals Inc
Onyx Pharmaceuticals Inc
Peregrine Pharmaceuticals Inc
Pfizer
Philogen Srl
ProStrakan Group Plc
Ranbaxy Laboratories Limited
Regeneron Pharmaceuticals Inc
sanofi-aventis
Schering-Plough
Shionogi
Siemens Medical Solutions
Stanford University
Syndax Pharmaceuticals Inc
Taisho Pharmaceutical
Titan Pharmaceuticals
Vaccinex Inc
Warner Chilcott
Xanthus Pharmaceuticals Inc
Zilip-Pharma
ZymoGenetics Inc

APPENDIX 3 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

Subsidiaries
Joint-venture Companies

APPENDIX 5 - PRODUCT INDEX

LIST OF TABLES

Principal Operating Results
Capital Expenditure by Business Area
Capital Expenditure by Geographic Area
Research and Development Expenditure by Business Area
Research and Development by Geographic Area
Sales by Business Area
Operating Income (Loss) by Business Area
Sales by Destination
Sales by Origin
Operating Income (Loss) by Geographical Area
Recent Product Approvals
Major Products, Therapeutic Areas And Sales
Avalox/Avelox Sales by Company (2008-2016)
Levitra Sales by Company (2008-2016)
Interferon Beta-1b Sales by Company (2008-2016)
Xarelto Sales by Company (2008-2016)
Riociguat Sales (2012-2016)
Nexavar Sales by Indication (2008-2016)
Alpharadin Sales by Indication (2013-2016)

LIST OF CHARTS

Sales, Costs and Operating Income
Capital Expenditure by Business Area, 2009
Research and Development by Geographic Area, 2009
Sales by Business Area, 2009
Operating Income by Business Area
Sales by Destination
Operating Income by Geographical Area
Sales of Current Major Products (2008-2016)
Sales By Major Product, 2009
Avalox/Avelox Sales by Company (2008-2016)
Bayer's Sales of Cipro/Ciprobay (2008-2016)
Glucobay Sales (2008-2016)
Levitra Sales by Company (2008-2016)
Interferon Beta-1b Sales by Company (2008-2016)
Bayer's Sales of Adalat (2008-2016)
Kogenate Sales (2008-2016)
Xarelto Sales by Company (2009-2016)
Riociguat Sales (2012-2016)
Nexavar’s Dual Mode of Action
Nexavar Total Sales (2008-2016)
Nexavar Sales by Indication, 2009
Nexavar Sales by Indication, 2016
Alpharadin Sales (2013-2016)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity
Skip to top


Alcon: Pipeline, Products, Performance, Potential US$ 1,040.00 Feb, 2010 · 52 pages
Amgen: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2010 · 132 pages
Novartis: Pipeline, Products, Performance, Potential US$ 1,040.00 Mar, 2011 · 218 pages
Pfizer: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2010 · 228 pages

Ask Your Question

Bayer: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: